Fennec Pharmaceuticals (FENC)

Fennec Pharmaceuticals (FENC) Stock Price & Analysis


FENC Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$7.02 - $10.85
Previous Close$7.15
Average Volume (3M)57.07K
Market Cap
Enterprise Value$246.56M
Total Cash (Recent Filing)$23.77M
Total Debt (Recent Filing)$24.90M
Price to Earnings (P/E)-7.1
Nov 14, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.00
Shares Outstanding26,361,399
10 Day Avg. Volume73,452
30 Day Avg. Volume57,069
Standard Deviation0.14
Financial Highlights & Ratios
Price to Book (P/B)-103.54
Price to Sales (P/S)90.49
Price to Cash Flow (P/CF)-9.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue160.62
Enterprise Value/Gross Profit170.16
Enterprise Value/Ebitda-16.70
Price Target Upside113.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Fennec Pharmaceuticals’s price range in the past 12 months?
Fennec Pharmaceuticals lowest stock price was $7.02 and its highest was $10.85 in the past 12 months.
    What is Fennec Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Fennec Pharmaceuticals’s upcoming earnings report date?
    Fennec Pharmaceuticals’s upcoming earnings report date is Nov 14, 2023 which is in 45 days.
      How were Fennec Pharmaceuticals’s earnings last quarter?
      Fennec Pharmaceuticals released its earnings results on Aug 03, 2023. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.157 by -$0.053.
        Is Fennec Pharmaceuticals overvalued?
        According to Wall Street analysts Fennec Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Fennec Pharmaceuticals pay dividends?
          Fennec Pharmaceuticals does not currently pay dividends.
          What is Fennec Pharmaceuticals’s EPS estimate?
          Fennec Pharmaceuticals’s EPS estimate is -$0.11.
            How many shares outstanding does Fennec Pharmaceuticals have?
            Fennec Pharmaceuticals has 26,566,467 shares outstanding.
              What happened to Fennec Pharmaceuticals’s price movement after its last earnings report?
              Fennec Pharmaceuticals reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.157. Following the earnings report the stock price went down -7.292%.
                Which hedge fund is a major shareholder of Fennec Pharmaceuticals?
                Currently, no hedge funds are holding shares in FENC


                Fennec Pharmaceuticals Stock Smart Score

                The Fennec Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                Fennec Pharmaceuticals

                Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric cancer patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.


                Top 5 ETFs holding FENC

                Market Value
                Smart Score
                Vanguard Russell 3000 ETF
                Up to five ETFs with an Outperform Smart Score that hold FENC. The ETFs are listed according to market value of FENC within the ETF

                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Protagonist Therapeutics
                Acorda Therapeutics
                Sarepta Therapeutics

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis